Keros Therapeutics
KROS
166 hedge funds and large institutions have $409M invested in Keros Therapeutics in 2025 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 39 increasing their positions, 73 reducing their positions, and 26 closing their positions.
130% more call options, than puts
Call options by funds: $10.4M | Put options by funds: $4.54M
58% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 26
7% more funds holding
Funds holding: 155 → 166 (+11)
20.97% less ownership
Funds ownership: 86.87% → 65.89% (-21%)
27% less capital invested
Capital invested by funds: $559M → $409M (-$150M)
47% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 73
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$18.9M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$8.44M |
| 3 |
Renaissance Technologies
New York
|
+$7.67M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$5.2M |
| 5 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$4.46M |
Top Sellers
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$94.2M |
| 2 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$34.6M |
| 3 |
MAP
Madison Avenue Partners
New York
|
-$33.1M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$22.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$20.9M |
KROS Hedge Fund Activity: Q4 2025 in Review
166 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q4 2025, worth a combined $409M — down 27% from $559M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new KROS positions and 26 closed out — a net gain of 15 holders — while 39 added to existing stakes and 73 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $18.9M. The largest seller was ADAR1 Capital Management, cutting an estimated $94.2M.
- 166 institutional investors held Keros Therapeutics (KROS) as of Q4 2025, up from 155 in Q3 2025.
- Funds reported $409M of Keros Therapeutics stock for Q4 2025, down 27% quarter-over-quarter.
- 41 funds opened new Keros Therapeutics positions in Q4 2025 and 26 closed out, a net change of +15 holders.
- The largest Keros Therapeutics buyer in Q4 2025 was Arrowstreet Capital, an estimated $18.9M added.
- The largest Keros Therapeutics seller in Q4 2025 was ADAR1 Capital Management, an estimated $94.2M sold.
Based on aggregated 13F filings for Q4 2025.